Combining Transarterial Chemoembolisation With Reduced Deubiquitinase Activity Reduces Hepatocellular Carcinoma Progression
Journal of Cellular and Molecular Medicine · 2026-06 · 30 (12)
DOI: 10.1111/jcmm.71209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 15.06.2026. Verfasst von Yun Tao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intervention, The Affiliated Hospital of Jiangnan University, Wuxi, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Ubiquitin Thiolesterase, Chemoembolization, Therapeutic. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Commission Surface Project of Wuxi City, Jiangsu Province, Clinical Research and Translational Medicine Research Project of The Affiliated Hospital of Jiangnan University.
Abstract (Originalsprache)
To investigate the interplay between ubiquitin‐specific protease 21 (USP21) and programmed death‐ligand 1 (PD‐L1) in the context of Transarterial chemoembolisation (TACE) treatment for hepatocellular carcinoma (HCC) and explore a novel combinatorial strategy to enhance therapeutic efficacy. USP21 was silenced in HCC cells and in two distinct mouse models: a diethylnitrosamine (DEN)‐induced orthotopic HCC model and a HepG2 subcutaneous xenograft model. The effects of USP21 knockdown, TACE and their combination on tumour growth, proliferation, invasion and apoptosis were evaluated. The regulation of PD‐L1 by USP21 was studied through co‐immunoprecipitation and deubiquitination assays. Rescue experiments were performed by overexpressing PD‐L1. Silencing USP21 attenuated HCC cell proliferation and invasion. Combining TACE with USP21 knockdown significantly enhanced antitumour effects compared to monotherapies. USP21 interacted with and deubiquitinated PD‐L1, stabilising its expression. Cycloheximide chase assays with densitometric quantification demonstrated that USP21 significantly prolonged the half‐life of PD‐L1 protein. Overexpression of PD‐L1 reversed the inhibitory effects of USP21 silencing and the enhanced therapeutic efficacy of the TACE/USP21 knockdown combination. USP21 stabilises PD‐L1 through deubiquitination, promoting HCC progression and immune evasion. Silencing USP21 enhances the therapeutic efficacy of TACE by modulating PD‐L1 expression, suggesting a promising combinatorial strategy for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Intervention, The Affiliated Hospital of Jiangnan University, Wuxi, China.
ORCID-Profile: Jie Li
Förderung
- Health Commission Surface Project of Wuxi City, Jiangsu Province
- Clinical Research and Translational Medicine Research Project of The Affiliated Hospital of Jiangnan University
Zitieren
APA
Tao, Y., Yu, W., Yang, W., Wu, Q., & Li, J. (2026). Combining Transarterial Chemoembolisation With Reduced Deubiquitinase Activity Reduces Hepatocellular Carcinoma Progression. Journal of Cellular and Molecular Medicine, 30(12). https://doi.org/10.1111/jcmm.71209
Vancouver
Tao Y, Yu W, Yang W, Wu Q, Li J. Combining Transarterial Chemoembolisation With Reduced Deubiquitinase Activity Reduces Hepatocellular Carcinoma Progression. Journal of Cellular and Molecular Medicine. 2026;30(12). doi:10.1111/jcmm.71209
BibTeX
@article{Tao2026,
author = {Tao, Yun and Yu, Wenhui and Yang, Wenge and Wu, Qinghua and Li, Jie},
title = {Combining Transarterial Chemoembolisation With Reduced Deubiquitinase Activity Reduces Hepatocellular Carcinoma Progression},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {12},
doi = {10.1111/jcmm.71209}
}
EUVIMED